Pataday Switch Approval Dilates Eye Drop Category As Alcon's OTC Sales Driver

 
• By Malcolm Spicer

With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.

Alcon US office

Leading the US in branded OTC product sales doesn’t make eye drops a strength for Alcon Laboratories Inc., but it says adding nonprescription sales of two concentrations of olopadatine will turn the category into a sales driver.

“The eye allergy area for us is probably the smaller portion of our OTC portfolio,” said Sean Clark,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rx-to-OTC Switch

More from Health